Immvention Therapeutix is partnering with Novo Nordisk to develop oral treatments for sickle cell disease (SCD) and other ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Many individuals with sickle cell anemia undergoing controlled ovarian ... cell disease in which there is homozygosity for the mutation that causes HbS. Sickle-cell anaemia is also referred ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

Stem cell transplant in young adults and adolescents with severe sickle cell disease may be a feasible option, according to a ...

FRIDAY, Jan. 24, 2025 (HealthDay News) -- People with sickle cell disease often struggle with memory, focus, learning and problem solving, setting them back in school and the workplace. That could be ...

Reference: “Brain Age Modeling and Cognitive Outcomes in Young Adults With and Without Sickle Cell Anemia” by Andria L. Ford, Slim Fellah, Yan Wang, Kira Unger-Levinson, Maria Hagan, Martin N. Reis, ...

Overall, the life expectancy of patients with SCD is lower than that of persons without SCD. 1 However, life expectancy varies depending on the type of disease, treatments administered, and ...

DURHAM, NC, USA I2, 2025 I IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human ...

This collaboration represents a significant milestone for IMMvention and reinforces our vision to address unmet needs in sickle cell disease and beyond,” said Anil Goyal, Ph.D., CEO and Co-found ...

Sickle cell anaemia occurs when red blood cells change shape under low oxygen conditions, transforming into a sickle shape that can block blood flow. This blockage can result in pain in the ...